Tsh Financial Statements From 2010 to 2024
| 8432 Stock | TWD 69.70 0.90 1.31% |
Check Tsh Biopharmoration financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tsh Biopharmoration's main balance sheet or income statement drivers, such as , as well as many indicators such as . Tsh financial statements analysis is a perfect complement when working with Tsh Biopharmoration Valuation or Volatility modules.
Tsh |
tsh biopharmoration Company Current Valuation Analysis
Tsh Biopharmoration's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Tsh Biopharmoration Current Valuation | 1.17 B |
Most of Tsh Biopharmoration's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, tsh biopharmoration is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, tsh biopharmoration has a Current Valuation of 1.17 B. This is 91.85% lower than that of the Healthcare sector and 99.36% lower than that of the Drug Manufacturers - Major industry. The current valuation for all Taiwan stocks is 92.96% higher than that of the company.
tsh biopharmoration Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tsh Biopharmoration's current stock value. Our valuation model uses many indicators to compare Tsh Biopharmoration value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tsh Biopharmoration competition to find correlations between indicators driving Tsh Biopharmoration's intrinsic value. More Info.tsh biopharmoration is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.61 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for tsh biopharmoration is roughly 1.64 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tsh Biopharmoration's earnings, one of the primary drivers of an investment's value.About Tsh Biopharmoration Financial Statements
Tsh Biopharmoration investors use historical fundamental indicators, such as Tsh Biopharmoration's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tsh Biopharmoration. Please read more on our technical analysis and fundamental analysis pages.
TSH Biopharm Corporation Limited develops, manufactures, and markets drugs for various chronic diseases in Taiwan and China. TSH Biopharm Corporation Limited is a subsidiary of TTY Biopharm Company Limited. TSH BIOPHARM is traded on Taiwan OTC Exchange in Taiwan.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Tools for Tsh Stock Analysis
When running Tsh Biopharmoration's price analysis, check to measure Tsh Biopharmoration's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tsh Biopharmoration is operating at the current time. Most of Tsh Biopharmoration's value examination focuses on studying past and present price action to predict the probability of Tsh Biopharmoration's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tsh Biopharmoration's price. Additionally, you may evaluate how the addition of Tsh Biopharmoration to your portfolios can decrease your overall portfolio volatility.